Improve Medical Instruments Co., Ltd. Class A

Improve Medical Instruments Co., Ltd. Class A

SSZSE:300030
6.27
CNY
-0.76
(-10.81%)
0.04EPS
228.84P/E
2.14BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Improve Medical Instruments Co., Ltd. Class A carries a market capitalization of 2.14B, placing it among publicly traded companies globally. Its enterprise value stands at 2.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.14B
Enterprise Value2.09B

Share Statistics

As of September 30, 2026, Improve Medical Instruments Co., Ltd. Class A has 309.19M shares outstanding.

Shares Outstanding309.19M

Valuation Ratios

As of September 30, 2026, Improve Medical Instruments Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 228.84. The price-to-sales ratio is 4.28, and the price-to-book ratio stands at 3.35.

PE Ratio228.84
PS Ratio4.28
PB Ratio3.35
P/TBV Ratio3.52

Enterprise Valuation

As of September 30, 2026, Improve Medical Instruments Co., Ltd. Class A trades at an EV/EBITDA multiple of 99.97 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 99.97 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.09B versus a market cap of 2.14B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales4.18
EV / EBITDA99.97
EV / EBIT99.97

Financial Position

As of September 30, 2026, Improve Medical Instruments Co., Ltd. Class A maintains a current ratio of 1.60, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.02, indicating elevated leverage, while an interest coverage ratio of 6.78 demonstrates adequate ability to service its debt obligations.

Current Ratio1.60
Quick Ratio0.63
Debt / Equity9.02
Debt / EBITDA2.88
Interest Coverage6.78

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 791,900.04 in revenue per employee across its workforce of 632.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee791,900.04
Employee Count632.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Improve Medical Instruments Co., Ltd. Class A recorded 10.72M in income tax expense. That works out to an effective tax rate of 47.92, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 22.38M, leaving 9.35M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax10.72M
Effective Tax Rate47.92

Stock Price Statistics

CNY

As of the close on November 17, 2026, Improve Medical Instruments Co., Ltd. Class A's stock has declined approximately 24.46% over the past 52 weeks. The 50-day moving average sits at 6.75, while the 200-day moving average is 7.19.

52-Week Price Change-24.46%
50-Day Moving Average6.75
200-Day Moving Average7.19

Income Statement

CNY

Over the twelve months ended September 30, 2026, Improve Medical Instruments Co., Ltd. Class A generated 500.48M in revenue and converted that into 9.35M in net income, yielding earnings per share of 0.04. EBITDA reached 20.93M, while operating income came in at 67.43M.

Revenue500.48M
Gross Profit219.91M
Operating Income67.43M
Pretax Income22.38M
Net Income9.35M
EBITDA20.93M
EBIT20.93M
Earnings Per Share (EPS)0.04

Balance Sheet

CNY

As of September 30, 2026, Improve Medical Instruments Co., Ltd. Class A holds 137.10M in cash and equivalents against 60.30M in total debt, resulting in a net debt position of -64.28M. Total book value stands at 639.29M, with working capital of 129.60M providing operational flexibility.

Cash & Cash Equivalents137.10M
Total Debt60.30M
Net Debt-64.28M
Equity (Book Value)639.29M
Book Value Per Share2.07
Working Capital129.60M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-29.49M

Margins

Over the twelve months ended September 30, 2026, Improve Medical Instruments Co., Ltd. Class A posted a gross margin of 43.94, reflecting its pricing power and cost economics. The operating margin of 13.47 and net profit margin of 1.87 provide insight into operational efficiency.

Gross Margin43.94
Operating Margin13.47
Pretax Margin4.47
Profit Margin1.87
EBITDA Margin4.18

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Improve Medical Instruments Co., Ltd. Class A paid dividends of 0.01 per share. The dividend payout ratio of 21.22 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 6.89, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Improve Medical Instruments Co., Ltd. Class A shareholders.

Dividend Per Share0.01
Payout Ratio21.22
Shareholder Yield6.89

Stock Splits

Improve Medical Instruments Co., Ltd. Class A's most recent stock split took place on April 25, 2014 with a 1:2 split ratio.

Last Split Date4/25/2014
Split Ratio1:2

Scores

As of September 30, 2026, Improve Medical Instruments Co., Ltd. Class A has an Altman Z-Score of 5.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.71